Prognostic impact of metabolic syndrome in patients with primary endometrial cancer: a retrospective bicentric study.
Endometrial cancer
Metabolic syndrome
Obesity
Survival
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
03 Apr 2024
03 Apr 2024
Historique:
received:
26
12
2023
accepted:
13
03
2024
medline:
4
4
2024
pubmed:
4
4
2024
entrez:
3
4
2024
Statut:
epublish
Résumé
Endometrial cancer (EC) is the most common gynaecological cancer. Its incidence has been rising over the years with ageing and increased obesity of the high-income countries' populations. Metabolic syndrome (MetS) has been suggested to be associated with EC. The aim of this study was to assess whether MetS has a significant impact on oncological outcome in patients with EC. This retrospective study included patients treated for EC between January 2010 and December 2020 in two referral oncological centers. Obesity, arterial hypertension (AH) and diabetes mellitus (DM) were criteria for the definition of MetS. The impact of MetS on progression free survival (PFS) and overall survival (OS) was assessed with log-rank test and Cox regression analyses. Among the 415 patients with a median age of 64, 38 (9.2%) fulfilled the criteria for MetS. The median follow-up time was 43 months. Patients suffering from MetS did not show any significant differences regarding PFS (36.0 vs. 40.0 months, HR: 1.49, 95% CI 0.79-2.80 P = 0.210) and OS (38.0 vs. 43.0 months, HR: 1.66, 95% CI 0.97-2.87, P = 0.063) compared to patients without MetS. Patients with obesity alone had a significantly shorter median PFS compared to patients without obesity (34.5 vs. 44.0 months, P = 0.029). AH and DM separately had no significant impact on PFS or OS (p > 0.05). In our analysis, MetS in patients with EC was not associated with impaired oncological outcome. However, our findings show that obesity itself is an important comorbidity associated with significantly reduced PFS.
Identifiants
pubmed: 38570343
doi: 10.1007/s00432-024-05699-1
pii: 10.1007/s00432-024-05699-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
174Informations de copyright
© 2024. The Author(s).
Références
Arcidiacono B, Iiritano S, Nocera A, Possidente K, Nevolo MT, Ventura V et al (2012) Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. Exp Diabetes Res 2012:789174
doi: 10.1155/2012/789174
pubmed: 22701472
pmcid: 3372318
Balkau B, Charles MA (1999) Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 16(5):442–3
doi: 10.1046/j.1464-5491.1999.00059.x
pubmed: 10342346
Bing RS, Tsui WL, Ding DC (2022) The association between diabetes mellitus, high monocyte/lymphocyte ratio, and survival in endometrial cancer: a retrospective cohort study. Diagnostics (Basel) 13(1):44
doi: 10.3390/diagnostics13010044
pubmed: 36611336
Bjorge T, Stocks T, Lukanova A, Tretli S, Selmer R, Manjer J et al (2010) Metabolic syndrome and endometrial carcinoma. Am J Epidemiol 171(8):892–902
doi: 10.1093/aje/kwq006
pubmed: 20219764
Byers T, Sedjo RL (2015) Body fatness as a cause of cancer: epidemiologic clues to biologic mechanisms. Endocr Relat Cancer 22(3):R125–R134
doi: 10.1530/ERC-14-0580
pubmed: 25870250
Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S et al (2021) ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 31(1):12–39
doi: 10.1136/ijgc-2020-002230
pubmed: 33397713
Kokts-Porietis RL, McNeil J, Nelson G, Courneya KS, Cook LS, Friedenreich CM (2020) Prospective cohort study of metabolic syndrome and endometrial cancer survival. Gynecol Oncol 158(3):727–733
doi: 10.1016/j.ygyno.2020.06.488
pubmed: 32600790
Kyo S, Nakayama K (2020) Endometrial cancer as a metabolic disease with dysregulated PI3K signaling: shedding light on novel therapeutic strategies. Int J Mol Sci 21(17):6073
doi: 10.3390/ijms21176073
pubmed: 32842547
pmcid: 7504460
Li X, Yang X, Cheng Y, Dong Y, Wang J, Wang J (2023) Development and validation of a prognostic model based on metabolic risk score to predict overall survival of endometrial cancer in Chinese patients. J Gynecol Oncol. https://doi.org/10.3802/jgo.2023.34.e69
doi: 10.3802/jgo.2023.34.e69
pubmed: 38216135
pmcid: 10948987
Luo J, Beresford S, Chen C, Chlebowski R, Garcia L, Kuller L et al (2014) Association between diabetes, diabetes treatment and risk of developing endometrial cancer. Br J Cancer 111(7):1432–1439
doi: 10.1038/bjc.2014.407
pubmed: 25051408
pmcid: 4183842
Mitsuhashi A, Kiyokawa T, Sato Y, Shozu M (2014) Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial. Cancer 120(19):2986–2995
doi: 10.1002/cncr.28853
pubmed: 24917306
Modesitt SC, Geffel DL, Via J, Weltman AL (2012) Morbidly obese women with and without endometrial cancer: are there differences in measured physical fitness, body composition, or hormones? Gynecol Oncol 124(3):431–6
doi: 10.1016/j.ygyno.2011.11.013
pubmed: 22101155
Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E (2016) Endometrial cancer. Lancet 387(10023):1094–1108
doi: 10.1016/S0140-6736(15)00130-0
pubmed: 26354523
Palmisano BT, Zhu L, Stafford JM (2017) Role of estrogens in the regulation of liver lipid metabolism. Adv Exp Med Biol 1043:227–256
doi: 10.1007/978-3-319-70178-3_12
pubmed: 29224098
pmcid: 5763482
Pecorelli S (2009) Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105(2):103–104
doi: 10.1016/j.ijgo.2009.02.012
pubmed: 19367689
Perez-Martin AR, Castro-Eguiluz D, Cetina-Perez L, Velasco-Torres Y, Bahena-Gonzalez A, Montes-Servin E et al (2022) Impact of metabolic syndrome on the risk of endometrial cancer and the role of lifestyle in prevention. Bosn J Basic Med Sci 22(4):499–510
pubmed: 35276057
pmcid: 9392984
Raglan O, Kalliala I, Markozannes G, Cividini S, Gunter MJ, Nautiyal J et al (2019) Risk factors for endometrial cancer: an umbrella review of the literature. Int J Cancer 145(7):1719–1730
doi: 10.1002/ijc.31961
pubmed: 30387875
Rochlani Y, Pothineni NV, Kovelamudi S, Mehta JL (2017) Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Ther Adv Cardiovasc Dis 11(8):215–225
doi: 10.1177/1753944717711379
pubmed: 28639538
pmcid: 5933580
Romanos-Nanclares A, Tabung FK, Sinnott JA, Trabert B, De Vivo I, Playdon MC et al (2023) Inflammatory and insulinemic dietary patterns and risk of endometrial cancer among US women. J Natl Cancer Inst 115(3):311–321
doi: 10.1093/jnci/djac229
pubmed: 36515492
Rosato V, Zucchetto A, Bosetti C, Dal Maso L, Montella M, Pelucchi C et al (2011) Metabolic syndrome and endometrial cancer risk. Ann Oncol 22(4):884–889
doi: 10.1093/annonc/mdq464
pubmed: 20937645
Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer Statistics, 2021. CA Cancer J Clin 71(1):7–33
doi: 10.3322/caac.21654
pubmed: 33433946
Soslow RA, Tornos C, Park KJ, Malpica A, Matias-Guiu X, Oliva E et al (2019) Endometrial carcinoma diagnosis: use of FIGO grading and genomic subcategories in clinical practice: recommendations of the international society of gynecological pathologists. Int J Gynecol Pathol. 38(Suppl 1):S64–S74
doi: 10.1097/PGP.0000000000000518
pubmed: 30550484
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249
doi: 10.3322/caac.21660
pubmed: 33538338
Tang YL, Zhu LY, Li Y, Yu J, Wang J, Zeng XX et al (2017) Metformin use is associated with reduced incidence and improved survival of endometrial cancer: a meta-analysis. Biomed Res Int 2017:5905384
doi: 10.1155/2017/5905384
pubmed: 28409158
pmcid: 5376924
Yang X, Li X, Dong Y, Fan Y, Cheng Y, Zhai L et al (2021) Effects of metabolic syndrome and its components on the prognosis of endometrial cancer. Front Endocrinol (Lausanne) 12:780769
doi: 10.3389/fendo.2021.780769
pubmed: 34975754
Yin XH, Jia HY, Xue XR, Yang SZ, Wang ZQ (2014) Clinical analysis of endometrial cancer patients with obesity, diabetes, and hypertension. Int J Clin Exp Med 7(3):736–743
pubmed: 24753771
pmcid: 3992416
Yin F, Shao X, Zhao L, Li X, Zhou J, Cheng Y et al (2019) Predicting prognosis of endometrioid endometrial adenocarcinoma on the basis of gene expression and clinical features using Random Forest. Oncol Lett 18(2):1597–1606
pubmed: 31423227
pmcid: 6607378
Zhao Y, Sun H, Feng M, Zhao J, Zhao X, Wan Q et al (2018) Metformin is associated with reduced cell proliferation in human endometrial cancer by inbibiting PI3K/AKT/mTOR signaling. Gynecol Endocrinol 34(5):428–432
doi: 10.1080/09513590.2017.1409714
pubmed: 29182407